2,847 Shares in DexCom, Inc. (NASDAQ:DXCM) Bought by SageView Advisory Group LLC

SageView Advisory Group LLC bought a new position in shares of DexCom, Inc. (NASDAQ:DXCM) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 2,847 shares of the medical device company’s stock, valued at approximately $344,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Capital Research Global Investors raised its position in shares of DexCom by 21.4% during the fourth quarter. Capital Research Global Investors now owns 15,296,032 shares of the medical device company’s stock worth $1,898,085,000 after acquiring an additional 2,695,296 shares during the last quarter. Sands Capital Management LLC raised its holdings in DexCom by 10.2% during the 4th quarter. Sands Capital Management LLC now owns 15,058,806 shares of the medical device company’s stock worth $1,868,647,000 after purchasing an additional 1,398,136 shares during the last quarter. Capital World Investors lifted its position in shares of DexCom by 130.7% in the 4th quarter. Capital World Investors now owns 9,278,685 shares of the medical device company’s stock worth $1,151,392,000 after purchasing an additional 5,256,092 shares during the period. Artisan Partners Limited Partnership boosted its stake in shares of DexCom by 164.8% in the 4th quarter. Artisan Partners Limited Partnership now owns 5,900,308 shares of the medical device company’s stock valued at $732,169,000 after purchasing an additional 3,672,471 shares during the last quarter. Finally, Norges Bank acquired a new stake in shares of DexCom during the fourth quarter worth $540,178,000. 97.75% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

DXCM has been the topic of a number of research analyst reports. Citigroup upped their price target on shares of DexCom from $148.00 to $161.00 and gave the company a “buy” rating in a research report on Wednesday, April 3rd. UBS Group lifted their target price on DexCom from $153.00 to $163.00 and gave the stock a “buy” rating in a report on Wednesday, April 10th. Royal Bank of Canada initiated coverage on DexCom in a report on Tuesday, March 12th. They set an “outperform” rating and a $165.00 price target on the stock. Redburn Atlantic initiated coverage on shares of DexCom in a research note on Thursday, May 30th. They issued a “neutral” rating and a $130.00 price objective for the company. Finally, Canaccord Genuity Group increased their target price on shares of DexCom from $144.00 to $145.00 and gave the stock a “buy” rating in a research note on Friday, April 26th. Four investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, DexCom has a consensus rating of “Moderate Buy” and a consensus price target of $140.94.

DexCom Stock Performance

Shares of DXCM opened at $116.64 on Thursday. DexCom, Inc. has a 52 week low of $74.75 and a 52 week high of $142.00. The company has a debt-to-equity ratio of 1.08, a quick ratio of 2.53 and a current ratio of 2.90. The stock has a 50 day moving average price of $126.16 and a two-hundred day moving average price of $125.92. The firm has a market capitalization of $46.39 billion, a P/E ratio of 75.25, a P/E/G ratio of 2.85 and a beta of 1.22.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, April 25th. The medical device company reported $0.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.27 by $0.05. DexCom had a return on equity of 31.01% and a net margin of 16.82%. The business had revenue of $921.00 million during the quarter, compared to the consensus estimate of $911.20 million. Equities analysts forecast that DexCom, Inc. will post 1.78 earnings per share for the current fiscal year.

Insider Activity

In related news, EVP Sadie Stern sold 4,137 shares of the business’s stock in a transaction dated Monday, March 25th. The shares were sold at an average price of $140.00, for a total transaction of $579,180.00. Following the transaction, the executive vice president now directly owns 76,304 shares in the company, valued at $10,682,560. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, EVP Michael Jon Brown sold 2,624 shares of the firm’s stock in a transaction on Thursday, March 28th. The stock was sold at an average price of $140.04, for a total transaction of $367,464.96. Following the completion of the sale, the executive vice president now directly owns 68,682 shares of the company’s stock, valued at approximately $9,618,227.28. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, EVP Sadie Stern sold 4,137 shares of the business’s stock in a transaction dated Monday, March 25th. The stock was sold at an average price of $140.00, for a total transaction of $579,180.00. Following the completion of the transaction, the executive vice president now directly owns 76,304 shares in the company, valued at $10,682,560. The disclosure for this sale can be found here. Insiders sold a total of 61,837 shares of company stock worth $8,490,675 over the last quarter. Insiders own 0.30% of the company’s stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.